COMMUNIQUÉS West-GlobeNewswire

Positive phase III results show Roche’s giredestrant significantly improved progression-free survival in ER-positive advanced breast cancer
22/09/2025
evERA met its co-primary endpoints; giredestrant plus everolimus demonstrated significant benefit in ITT and ESR1 -mutated populations in post-CDK inhibitor setting, compared with standard of care plus everolimus The [...]
Global expansion of Idorsia’s QUVIVIQ continues as Simcere launches in China
22/09/2025
Allschwil, Switzerland – September 22, 2025 Idorsia Ltd. (SIX: IDIA) announces that Simcere Pharmaceuticals Group Ltd (2096.HK, “Simcere”) has launched QUVIVIQ ® (daridorexant) in China. QUVIVIQ, Idorsia’s dual orexin [...]
L’essai de Phase II LANTIC d’Ipsen en esthétique démontre un profil clinique différencié à longue durée d'action, premier de sa classe pour l'IPN10200, permettant le lancement de l’étude de Phase III
22/09/2025
L'IPN10200 est une molécule recombinante, première de sa classe (« first-in-class »), spécifiquement conçue pour obtenir une affinité et une internalisation accrues du récepteur, offrant ainsi une durée d’action [...]
Press Release: Update on the US regulatory review of tolebrutinib in non-relapsing, secondary progressive multiple sclerosis
22/09/2025
Update on the US regulatory review of tolebrutinib in non-relapsing, secondary progressive multiple sclerosis Paris, September 22, 2025 . The US Food and Drug Administration (FDA) has extended by three months the target [...]
Ipsen’s LANTIC Phase II in aesthetics delivers a first-in-class, differentiated long-acting clinical profile for IPN10200, enabling the initiation of Phase III
22/09/2025
IPN10200 is a recombinant, first-in-class molecule uniquely engineered to generate increased receptor affinity and internalization that produces a longer duration of action, optimized for safety and efficacy Data showed [...]
Communiqué de presse : Mise à jour sur l’examen réglementaire américain du tolébrutinib dans le traitement de la sclérose en plaques secondairement progressive non récurrente
22/09/2025
Mise à jour sur l’examen réglementaire américain du tolébrutinib dans le traitement de la sclérose en plaques secondairement progressive non récurrente Paris, le 22 septembre 2025 . La Food and Drug Administration (FDA [...]
Press Release: Sanofi and Regeneron’s Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion
22/09/2025
Sanofi and Regeneron’s Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion Recommendation for adults and adolescents based on phase 3 studies showing Dupixent significantly reduced [...]
Communiqué de presse : Sanofi et Regeneron voient l’autorisation du Dupixent pour le traitement de l’urticaire chronique spontanée progresser dans l’UE grâce à un avis positif du CHMP
22/09/2025
Sanofi et Regeneron voient l’autorisation du Dupixent pour le traitement de l’urticaire chronique spontanée progresser dans l’UE grâce à un avis positif du CHMP Recommandation pour les adultes et les adolescents, sur la [...]
Dupixent® (dupilumab) to Treat Chronic Spontaneous Urticaria (CSU) Advances in EU with Positive CHMP Opinion
22/09/2025
Recommendation for adults and adolescents based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo If approved, Dupixent would be the first targeted medicine in over [...]
Yangtze River Pharmaceutical Group’s Innovative Anti-insomnia Drug Fazamorexant Debut at the World Sleep Congress 2025
22/09/2025
TAIZHOU, Jiangsu, Sept. 21, 2025 (GLOBE NEWSWIRE) -- Most recently, the Phase III pivotal clinical trial results of Fazamorexant, a first-class innovative anti-insomnia drug independently developed by Yangtze River [...]

Pages